Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease

Abstract

Background: Recent studies have shown that oxidative stress (OS) is the most important indicator in the pathogenesis of Alzheimer's disease (AD), but the results in previous studies are conflicting. This study aimed to assess the plasma levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) as DNA oxidative damage marker and total antioxidant capacity (TAC) in patients with AD versus control group.

Methods: Thirty patients with AD and 30 sex-and age-matched healthy subjects were studied. Diagnosis of AD was based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS/ADRDA) criteria. Also for the patients, Mini-Mental State Examination (MMSE), computed tomography (CT) scan and brain magnetic resonance imaging (MRI) were done. Plasma levels of 8-OHdG and TAC were measured by competitive ELISA method and ferric reducing antioxidant power (FRAP) assay, respectively.

Results: Plasma levels of 8-OHdG was significantly higher in AD compared to control group (p<0.001), while the total antioxidant was significantly lower in patients compared to controls (p=0.002). The value of area under the ROC curve for 8-OHdG and TAC in discriminating AD from controls were 0.87 and 0.32, respectively.

Conclusion: Our results indicate a link between oxidative stress and AD indicating a possible contributive role of these markers in the development of AD and as an indicator in the discrimination of AD from healthy controls.

Keywords: Alzheimer's disease, Oxidative stress, DNA damage, 8-OHdG, TAC.

Citation:
Moslemezad A, Mahjoub S, Moghadasi M. Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease. Caspian J Intern Med 2016; 7(2):88-92
8-OHdG is the most common marker of DNA oxidation produced by oxidation of DNA bases (5). Considering the importance of oxidative stress in Alzheimer's disease, therefore, we aimed to determine the plasma levels of 8-OHdG and TAC in AD patients and healthy controls. These data may provide additional data in the elucidation of pathogenesis as well as prevention of AD. In addition, reduction of oxidative stress may be helpful in the treatments for AD.

Methods
This case-control study was done on 30 patients with severe AD and 30 healthy subjects as the control group from Mehr-Avaran Shomal Nursing Home, Sari, Iran. The control and patient groups were matched by sex and age. Alzheimer's patient diagnosis was based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS/ADRDA) criteria and the Mini-Mental State Examination (MMSE) score of 0-10, computed tomography (CT) scan and brain magnetic resonance imaging (MRI) by a neurologist. Other causes of dementia were ruled out by imaging and laboratory tests. The control group had normal MMSE scores.

The study protocol was approved by the Ethics Committee of the Babol University of Medical Sciences. Informed consent was obtained from the comparisons or relatives of all patient participants. Subjects with inflammatory and infectious diseases such as anemia, diabetes, hepatitis, and also consumers of antioxidant and vitamins, and folic acid supplementations were excluded from our study. The blood samples were collected in sodium heparin tubes from fasting subjects. The separation of plasma was done by centrifugation at 1500 rpm for 10 min and stored at -80°C until measurement.

Measurement of Total Antioxidant Capacity (TAC): The ferric reducing antioxidant power (FRAP assay) is a method to determine TAC (total antioxidant capacity). According to this method, a blue ferrous complex is formed by reduction of colorful ferric-tripyridyltriazine complex in the presence of antioxidant. The absorbance of samples was determined at a wavelength of 593 nm. After comparing the absorbance of each sample to the standard curve, the quantity of antioxidant power was calculated and the TAC has reported in μmol/L (11).

Measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG): The 8-OHdG concentration was analyzed by competitive ELISA kit (Chongqing Biospes CO., Ltd). The unknown 8-OHdG samples or 8-OHdG standards were first added to an 8-OHdG/BSA conjugate preabsorbed ELISA plate. After a brief incubation, an anti-8OHdG monoclonal antibody was added, followed by an HRP conjugated secondary antibody.

After the addition of substrate solution to each well, a blue color was produced. Then the ELISA plate was incubated at room temperature for 30 min. Finally, stop solution was added and a yellow color was produced. The absorbance of samples were measured at 450 nm. The 8-OHdG content in unknown samples was determined by comparison with predetermined 8-OHdG standard curve. The concentration of 8-OHdG was reported in ng/ml (12).

Statistical analysis: Statistical analysis were done using SPSS Version 18. Results were expressed as mean±SEM for all parameters. The data analyses were performed using independent t-test. Also, Mann-Whitney test was used for data analysis with abnormal distribution. The receiver operative characteristic (ROC) curve was used for discrimination of AD patients from healthy controls. A p-value<0.05 was considered statistically significant.

Results
Demographic and medical features of the patients and control groups were shown in table 1. The two groups were similar in regard to age and sex (p>0.05) but significantly different regarding MMSE (p<0.001). The mean value of plasma 8-OHdG levels in AD was significantly higher than the control group (P<0.001).

While the TAC levels (P=0.002) in patients were significantly lower than controls (Table 2). The area under ROC curve (AUC) in plasma of patients for 8-OHdG and TAC were (0.87 and 0.32, respectively) (figure 1 and table 3).

Table 1: Demographic and medical features of the patients and control groups.

| Group Variable | Patient(n=30) Mean±SEM | Control(n=30) Mean±SEM | P value |
|----------------|------------------------|------------------------|---------|
| Age (years)    | 81±1.51                | 77.8±1.10              | 0.09    |
| Sex (F/M)      | 22.8                   | 22.8                   | 1.000   |
| MMSE           | 3.6±0.24               | 28.3±0.77              | <0.001  |

Abbreviations: MMSE, Mini-Mental State Examination
Table 2. Mean±SEM of oxidative stress markers in plasma of Alzheimer patients and control groups.

| Markers             | Mean±SEM | P value |
|---------------------|----------|---------|
| 8-OHdG (ng/mL)      |          |         |
| Case (n=30)         | 957.03±52.41 | <0.001 |
| Control (n=30)      | 572.23±35.06 |        |
| TAC (μmol/L)        |          |         |
| Case (n=30)         | 1140.63±69.03 | 0.002  |
| Control (n=30)      | 1364.48±12.62 |        |

Abbreviations: 8-OHdG, 8-hydroxy-2'-deoxyguanosine; TAC, Total antioxidant total; MMSE, Mini-Mental State Examination.

Figure 1: The area under ROC curve for 8-OHdG and TAC in plasma of Alzheimer patients

Table 3. Area under the ROC curve (AUC) of oxidative stress markers and total antioxidant capacity in plasma of Alzheimer patients and control subjects.

| Markers | AUC | Std. Error | Asymptotic sig. | Asymptotic 95% CI Lower bound | Asymptotic 95% CI Upper bound |
|---------|-----|------------|-----------------|--------------------------------|-----------------------------|
| 8-OHdG  | 0.87| 0.044      | 0.000**         | 0.785                          | 0.957                       |
| TAC     | 0.32| 0.080      | 0.018*          | 0.165                          | 0.479                       |

*P<0.05, **P<0.0001

Discussion

Our finding demonstrated a significantly higher plasma 8-OHdG concentration but significantly lower total antioxidant in AD versus healthy controls. Several studies reported similar results. In a study, Mecocci P et al. evaluated the levels of 8-OHdG on lymphocytes in AD patients and controls. They reported a significantly high 8-OHdG levels in the patients than controls (4). Similar to a previous study, Mecocci P et al. determined the status of lymphocytes 8-OHdG levels in AD patients and controls and reported that the levels of 8-OHdG were significantly higher in the patients (13).

In one study on 13 healthy and 13 AD patients, the level of 8-OHdG marker was assessed in the three regions of cerebral cortex and cerebellum in patient’s brain and the results showed a statistically significantly threefold increase in mitochondrial DNA (mtDNA) 8-OhdG levels in patients in comparison with the controls (14). This marker was also detectable in peripheral cells (13).

Since some antioxidants protect DNA from oxidative damage. Therefore, the increased 8-OHdG levels may be due to decrease in plasma antioxidants (4). Results of ROC analyses revealed that 8-OHdG can be considered as a possible marker to distinguish AD from healthy people. On the other hand, in the present study, total antioxidant capacity (TAC) levels significantly decreased in patients with AD in comparison to controls and this marker was evaluated by FRAP.

Critalli et al. assessed the plasma level of TAC in AD patients (mild, intermediate and advanced disease) versus control groups. They found significantly lower TAC in AD patients (all stages) as compared to control group (15). Also, Aldred et al. showed a significant changes in TAC (decrease) in severe AD with respect to controls (16). In another study, a significant decrease of TAC levels in AD patients was reported (17). Zifferla et al. observed low levels of plasma TAC in light-moderate and severe AD groups when compared to healthy control (18). This reduction might be due to malnutrition and high-speed production of free radicals in patients (4).

In contrast to the reported studies, some studies have not found a significant difference in plasma TAC between the AD and control groups (19, 20). According to the results obtained from our study, it seems the AD in advanced stages have higher levels of oxidative stress and lower levels of antioxidants. We demonstrated weak antioxidant defense system in patients with severe AD. Also, the level of DNA oxidative damage marker was higher. These subjects were very old with severe stage. So, lower levels of antioxidants and increased oxidative stress index may also be attributed to...
old age, malnutrition, lifestyle and irregularities in the antioxidant defense system. Since the subjects of the control group were at similar in age, thus the confounding effect of age on the results of this study should be ignored. However, although the patients with coexistent apparent clinical diseases were excluded, the influences of other factors particularly asymptomatic coexistent common chronic medical conditions such as diabetes, cardiovascular, chronic musculoskeletal disorders can not be ignored.

In Conclusion, the results of this study indicate a link between the damage caused by oxidative stress and AD and 8-OHdG marker may be used to differentiating subjects with and without AD. These findings need to be confirmed by further prospective longitudinal studies with adequate sample size.

Acknowledgments
We would like to thank the patient participants as well as the staff of the Mehr-Avaran-Shomal Nursing Home for their valuable cooperation in this project.

Funding: This work was financially supported by Babol University of Medical Sciences.

Conflict of Interest: There was no conflict of interest.

References
1. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr 2009; 3: 88-93.
2. Akhondzadeh S, Noroozian M, Mohammadi M, et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003; 28: 53-9.
3. Kenche VB, Barnham KJ. Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol 2011; 163: 211-9.
4. Mecocci P, Polidori M, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002; 59: 794-8.
5. Persson T, Popescu BO, Cezado-Minguez A. Oxidative stress in Alzheimer's disease: Why did antioxidant therapy fail? Oxid Med Cell Longev 2014; 2014: 427318.
6. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007; 43: 658-77.
7. Mahjoub S, Masrour Roudsari. Role of oxidative stress in pathogenesis of metabolic syndrome. Caspian J Intern Med 2012, 3: 386-96.
8. Dabidi RV, Hosseinzadeh S, Mahjoub S, Hosseinzadeh M, Myers J. Endurance exercise training and diferuloyl methane supplement: changes in neurotrophic factor and oxidative stress induced by lead in rat brain. Biol Sport 2013; 30: 41-6.
9. Hosseinzadeh S, Roshan VD, Mahjoub S. Continuous exercise training and curcumin attenuate changes in brain-derived neurotrophic factor and oxidative stress induced by lead acetate in the hippocampus of male rats. Pharm Biol 2013; 51: 240-5.
10. Shahandeheh M, Roshan VD, Hosseinzadeh S, Mahjoub S, Sarkisian V. Chronic exercise training versus acute endurance exercise in reducing neurotoxicity in rats exposed to lead acetate. Neural Regen Res 2013; 8: 714-22.
11. Benzie IF, Strain J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996; 239: 70-6.
12. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45. 1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76: 365-74.
13. Mecocci P, Polidori M, Ingegni T, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998; 51: 1014-7.
14. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747-51.
15. Cristalli DO, Arnal N, Marra FA, de Alaniz MJ, Marra CA. Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci 2012; 314: 48-56.
16. Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem 2010; 43: 267-71.
17. Sekler A, Jiménez JM, Rojo L, et al. Cognitive impairment and Alzheimer’s disease: Links with
oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat 2008; 4: 715-22.
18. Zafrilla P, Mulero J, Xandri J, et al. Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chemistry. 2006; 13: 1075-83.

19. Pulido R, Jiménez-Escrig A, Orensanz L, Saura-Calixto F. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 2005; 12: 531-5.
20. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 1998; 13: 840-5.